Clinical Development, Hormones and Insulin - Clinical Research Informer

(LAI-287 + semaglutide) by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) is under clinical development by Novo Nordisk and currently in Phase III for Type 2 Diabetes. LAI-287 + semaglutide) overview A fixed dose combination of GLP-1 analogue semaglutide and LAI-287, long-acting basal insulin is under development for the treatment of type 2 diabetes.

Insulin

Insulin Hormones Drugs Clinical Trials

Roche Invests $5.3B in Zealand’s Petrelintide, an Obesity Drug Candidate

XTalks

MARCH 17, 2025

Petrelintide, Zealand Pharmas long-acting amylin analog, is currently in Phase II clinical development and is designed for once-weekly subcutaneous injections. Amylin, a hormone co-secreted with insulin, plays a key role in regulating appetite by enhancing leptins effects the hormone that signals fullness after eating.

Hormones

Hormones Drugs Sales Insulin

Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approval

pharmaphorum

MAY 16, 2022

GLP-1 and GIP are hormones involved in blood sugar control and Mounjaro, a first-in-class medicine that activates both GLP-1 and GIP receptors, demonstrated improved blood sugar control. The findings were made via Lilly’s SURPASS phase 3 global clinical development programme, which comprised studies ranging from 40 to 52 weeks.

FDA Approval

FDA Approval Insulin Drugs Hormones

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Could an Antibody Drug Help You Shed Pounds?

The Pharma Data

NOVEMBER 2, 2020

That’s one finding from an early study that tested the injection drug, which mimics the effects of a natural hormone called fibroblast growth factor 21 (FGF21). FGF21 is a hormone that helps control metabolism by stimulating certain receptors in fat tissue, the liver, the pancreas and the central nervous system. MONDAY, Nov.

Antibody

Antibody Drugs Hormones Insulin

Tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes

The Pharma Data

JUNE 28, 2021

GIP is a hormone that may complement the effects of GLP-1. The SURPASS phase 3 global clinical development program for tirzepatide has enrolled more than 19,000 people with type 2 diabetes across 10 clinical trials, five of which are global registration studies. mg for four weeks and then reached the final dose of 1 mg.

Clinical Trials

Clinical Trials Clinical Trials Insulin Hormones

Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes

The Pharma Data

MARCH 5, 2021

GIP is a hormone that may complement the effects of GLP-1 receptor agonists. The SURPASS phase 3 global clinical development program for tirzepatide has enrolled more than 13,000 people with type 2 diabetes across 10 clinical trials, five of which are global registration studies. Source link:[link].

Clinical Trials

Clinical Trials Clinical Trials Trials Hormones

Tirzepatide’s superior A1C and body weight reductions versus placebo in adults with type 2 diabetes

The Pharma Data

JUNE 28, 2021

GIP is a hormone that may complement the effects of GLP-1. The SURPASS phase 3 global clinical development program for tirzepatide has enrolled more than 19,000 people with type 2 diabetes across 10 clinical trials, five of which are global registration studies. mg step), 10 mg (via steps at 2.5 mg, 5 mg and 7.5

Clinical Trials

Clinical Trials Clinical Trials Trials Hormones

Eli Lilly’s Tirzepatide Shows Promise for Keeping Prediabetic Patients Diabetes-Free

XTalks

NOVEMBER 21, 2024

These gut hormones are released in response to nutrient intake and play a crucial role in the incretin effect, which enhances insulin secretion. It’s the first and only approved dual agonist targeting both the GIP and GLP-1 receptors.

Sales

Sales Insulin Drugs Trials

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication

The Pharma Data

MARCH 11, 2021

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Trials

Trials Hormones Genome Genomics

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

The Pharma Data

JULY 23, 2021

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Hormones

Hormones Trials Genome Genomics

Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes

The Pharma Data

DECEMBER 15, 2020

The Phase III trial evaluated the use of the diabetes vaccine Diamyd ® , an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. People with type 1 diabetes cannot produce insulin.

Development

Development Insulin Drugs Clinical Trials

Diamyd Medical with MainlyAI and KTH awarded VINNOVA funding for AI driven sustainable production

The Pharma Data

DECEMBER 2, 2020

The new plant will as a first priority produce recombinant GAD65, the active pharmaceutical ingredient in the therapeutic diabetes vaccine Diamyd ® currently in late-stage clinical development. About Diamyd Medical Diamyd Medical develops therapies for type 1 diabetes.

Production

Production Insulin Vaccine Vaccination

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

The Pharma Data

APRIL 4, 2023

For Grade 2 or higher, initiate symptomatic treatment, including hormone replacement as clinically indicated. Initiate hormone replacement as indicated. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Hypophysitis can cause hypopituitarism.

FDA Approval

FDA Approval Containment Hormones Dermatology

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.

Sales

Sales Manufacturing FDA Approval Life Science

Clinical Research Informer

(LAI-287 + semaglutide) by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval

Roche Invests $5.3B in Zealand’s Petrelintide, an Obesity Drug Candidate

Webinars

Trending Sources

Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approval

Webinars

Could an Antibody Drug Help You Shed Pounds?

Tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes

Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes

Tirzepatide’s superior A1C and body weight reductions versus placebo in adults with type 2 diabetes

Eli Lilly’s Tirzepatide Shows Promise for Keeping Prediabetic Patients Diabetes-Free

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes

Diamyd Medical with MainlyAI and KTH awarded VINNOVA funding for AI driven sustainable production

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

Stay Connected